Table 1.
Sociodemographic and clinical characteristics of patients with metastatic genitourinary cancer (N = 60)
| Characteristics | N (%) |
|---|---|
| Gender | |
| Male | 41 (68.3) |
| Female | 19 (31.7) |
| Age | |
| M (SD; min-max) | 65.1 (13.1; 31–91) |
| Marital Status | |
| Single | 3 (5.0) |
| Married | 49 (81.7) |
| Divorced | 3 (5.0) |
| Widowed | 5 (8.3) |
| Education | |
| Elementary School | 4 (6.7) |
| High School | 5 (8.3) |
| Some College | 16 (26.7) |
| College Degree | 23 (38.3) |
| Beyond College | 12 (20.0) |
| Race | |
| White | 45 (75.0) |
| Hispanic | 5 (8.3) |
| Black | 2 (3.3) |
| Japanese | 3 (5.0) |
| Chinese | 2 (3.3) |
| East Asian | 2 (3.3) |
| South East Asian | 1 (1.7) |
| Annual Income | |
| Less than 40,000 | 4 (6.7) |
| 40,000 to 100,000 | 23 (38.3) |
| More than 100,000 | 33 (55.0) |
| Employment Status | |
| More than 32 h | 6 (10.0) |
| Less than 32 h | 6 (10.0) |
| Unemployed | 1 (1.7) |
| Homemaker | 2 (3.3) |
| Disability | 16 (26.7) |
| Retired | 29 (48.3) |
| Cancer | |
| Renal Cell Carcinoma | 38 (63.4) |
| Urothelial Carcinoma | 17 (28.3) |
| Prostate Cancer | 5 (8.3) |
| Immunotherapy | |
| Nivolumab | 21 (35.0) |
| Atezolizumab | 18 (30.0) |
| Nivolumab/Ipilimumab | 13 (21.7) |
| Pembrolizumab | 6 (10.0) |
| Avelumab | 2 (3.3) |
| Line of Therapy | |
| 1st line | 20 (33.3) |
| 2nd line | 27 (45.0) |
| 3rd line | 6 (10.0) |
| 4th line | 4 (6.7) |
| 5th line | 3 (5.0) |